Author: Fiona Craig

  • Hays Issues Q3 Trading Update and Sets Analyst Call

    Hays Issues Q3 Trading Update and Sets Analyst Call

    Hays plc (LSE:HAS) has published its trading update for the quarter ended 31 March 2026, offering insight into recent business performance. The statement is available via the London Stock Exchange and the company’s investor relations platform, and has also been filed with the UK regulator’s National Storage Mechanism.

    The group will host a conference call for analysts and investors on 16 April 2026 to discuss the latest developments in more detail. A recorded replay will be made accessible through its investor results centre, reflecting Hays’s ongoing commitment to maintaining open communication with the market.

    From an outlook perspective, the company faces pressure from weak technical indicators, with the share price trading below key moving averages and a negative MACD signal. Valuation also appears stretched, with a notably high price-to-earnings ratio of 748.65. Financial performance presents a mixed picture, with declining revenue and continued losses offset to some extent by improvements in free cash flow.

    More about Hays plc

    Hays plc is a global recruitment and workforce solutions provider, specialising in placing skilled professionals across a wide range of industries. The company operates across both permanent and temporary hiring markets, serving private and public sector clients in multiple regions worldwide.

  • Oriole Resources Reports High-Grade Gold Results from Eastern Cameroon Exploration

    Oriole Resources Reports High-Grade Gold Results from Eastern Cameroon Exploration

    Oriole Resources (LSE:ORR) has released new exploration findings from its 90%-owned Eastern Central Licence Package in Cameroon, located close to its 1.23-million-ounce Mbe gold resource. Ongoing work across the Ndom, Pokor, and Niambaram licences is reinforcing the potential for a large-scale gold system that could meaningfully increase the company’s overall resource base if current targets are validated.

    At the Ndom licence, selective rock-chip sampling has delivered grades of up to 17 grams per tonne gold from quartz veins that display structural characteristics similar to those seen at Mbe. These results have led to the planning of additional follow-up exploration. Meanwhile, at Pokor and Niambaram, soil and rock-chip programmes have identified lower-grade anomalies, with further mapping and assay work scheduled through 2026 to refine drill targets and guide future exploration priorities.

    From a financial standpoint, the company remains constrained by its lack of revenue generation and continued cash outflows, although it benefits from a relatively low level of debt. Technical signals provide some support, indicating moderate momentum, but valuation remains limited by negative earnings and the absence of dividend indicators.

    More about Oriole Resources PLC

    Oriole Resources PLC is an AIM-listed gold exploration and development company with a focus on Central and West Africa. Its flagship asset is the Mbe orogenic gold project in Cameroon, which hosts an inferred mineral resource of 1.23 million ounces. The company also holds a broader portfolio of early-stage exploration licences within the Eastern Central Licence Package, targeting further discoveries to build scale in the region.

  • Creo Medical Divests Manufacturing Unit in Strategic Shift to Outsourcing

    Creo Medical Divests Manufacturing Unit in Strategic Shift to Outsourcing

    Creo Medical (LSE:CREO) has agreed to sell its UK-based manufacturing division to a newly established company led by its current manufacturing management team, as part of a management buyout. Around 25 employees will transfer to the new entity, with production of Creo’s devices continuing under an outsourced model. The transaction reflects the company’s transition toward a leaner structure focused on product development and commercialisation, while maintaining operational continuity and technical expertise.

    The outsourcing arrangement is expected to deliver annual cost savings exceeding £1 million, representing an additional 15% reduction based on the FY25 closing run-rate on a pro forma basis. This builds on an estimated 40% cost reduction already achieved since FY24. By maintaining a close relationship with the new manufacturing business—where CEO Craig Gulliford will take on a non-executive role—Creo aims to scale production efficiently while concentrating resources on innovation and sales growth, reinforcing its position in the advanced medical device sector.

    Despite these operational efficiencies, the company’s financial outlook remains under pressure, with declining revenues, significant losses, and continued cash outflows. Market indicators offer some support, with a strong upward trend and positive MACD, although a high RSI suggests the stock may be overbought in the near term. The overall valuation impact is unclear, as key metrics such as price-to-earnings ratio and dividend yield are not currently available.

    More about Creo Medical

    Creo Medical Group is a UK-based medical technology company specialising in minimally invasive electrosurgical devices used in endoscopic procedures for pre-cancerous and cancerous conditions. Its CROMA platform, built on Kamaptive technology, combines multiple energy sources—including radiofrequency and microwave—into a single system to enable precise cutting, coagulation, dissection, and ablation. The company is focused on advancing a portfolio of patented solutions aimed at improving clinical outcomes while reducing the invasiveness and cost of surgical and endoscopic treatments.

  • Great Western Mining Advances Nevada Tungsten Project with Drilling Contractor Appointment

    Great Western Mining Advances Nevada Tungsten Project with Drilling Contractor Appointment

    Great Western Mining (LSE:GWMO) has appointed Major Drilling America to undertake a reverse circulation drilling programme at its wholly owned Defender-Pine Crow tungsten project in Mineral County, Nevada. The contract marks a key step in the company’s plan to establish a tungsten resource alongside its existing portfolio of copper, gold, and silver assets.

    The campaign will cover approximately 7,000 feet of drilling and is scheduled to begin in July, following preparatory groundworks in May. The programme is designed to support a maiden mineral resource estimate for Defender-Pine Crow, which the company is targeting for completion by late 2026. In addition, drilling will assess the extent and continuity of mineralisation across the Defender and Pine Crow zones, as well as the nearby M2 trend, potentially increasing the project’s overall scale and strategic value.

    Company management noted that the drilling forms part of a wider exploration effort that includes geological mapping, geophysical surveys, and additional channel sampling. These parallel initiatives aim to improve understanding of the broader mineralised system and strengthen the company’s positioning within the critical minerals space as the tungsten opportunity develops.

    Despite operational progress, the company’s financial profile remains a limiting factor, characterised by a lack of revenue, ongoing losses, and steady cash burn, albeit with relatively low debt levels. From a market standpoint, technical indicators are somewhat encouraging, with the share price holding above key averages and showing modest upward momentum. However, valuation remains difficult to justify due to negative earnings and the absence of dividend yield data.

    More about Great Western Mining

    Great Western Mining Corporation is an exploration and development company focused on strategic mineral assets across several fully owned claim groups in Mineral County, Nevada, a mining-friendly region in the United States. While maintaining exposure to copper, gold, and silver through projects such as Huntoon and tailings reprocessing initiatives, the company is increasingly prioritising tungsten as a critical mineral within its growth strategy.

  • Genedrive Expands Stroke Test Use at Southmead Hospital with Charity Funding

    Genedrive Expands Stroke Test Use at Southmead Hospital with Charity Funding

    Genedrive plc (LSE:GDR) has confirmed that its CYP2C19 ID Kit will be introduced at North Bristol NHS Trust’s Southmead Hospital, specifically within its Hyperacute and Acute Stroke Units. The rollout is supported by £80,000 in funding from the Medlock Charitable Trust, chaired by major shareholder David Medlock. The initiative is expected to benefit around 1,500 stroke patients treated at the hospital each year by helping clinicians quickly determine which individuals may not respond effectively to clopidogrel, a commonly prescribed antiplatelet drug.

    The funding will be administered through Southmead Hospital Charity, which enables enhancements to patient care beyond standard NHS resources. Meanwhile, the hospital’s stroke team is preparing a proposal to secure longer-term funding through the local Integrated Care Board once the initial programme concludes. Leaders from Genedrive, the Medlock Charitable Trust, and Bristol’s NHS services подчеркнули that the collaboration brings advanced point-of-care genetic testing into stroke aftercare, with the goal of tailoring treatment decisions, improving patient outcomes, and potentially lowering overall healthcare costs. The move also reinforces Genedrive’s role in advancing precision medicine within NHS pathways.

    From a financial standpoint, the company continues to face challenges, including persistent losses, ongoing cash outflows, and a declining equity base, albeit with limited debt exposure. Market indicators suggest some near-term strength, with the share price trading above key averages and a positive MACD reading, though a high RSI points to possible short-term overextension. Valuation remains difficult to justify given negative earnings and the absence of a meaningful price-to-earnings ratio.

    More about Genedrive

    Genedrive plc is a UK-based diagnostics company focused on pharmacogenetic testing solutions designed for rapid use at the point of care. Its products aim to support safer and more effective prescribing in acute and emergency settings. Key offerings include the CYP2C19 ID Kit, used to guide antiplatelet therapy in stroke patients, and the MT-RNR1 ID Kit, which helps prevent antibiotic-related hearing loss in newborns. The company is working to integrate precision diagnostics into routine NHS practice while also pursuing opportunities for international expansion.

  • Mindflair Supports Audrey AI with $1.8m Pre-Seed to Transform Audit Processes

    Mindflair Supports Audrey AI with $1.8m Pre-Seed to Transform Audit Processes

    Mindflair plc (LSE:MFAI) has revealed that Sure Valley Ventures Fund III, in which it is an investor, has led a $1.8 million pre-seed funding round for Audrey AI, a Dublin-based startup focused on building an AI-driven platform for financial auditors. The capital injection will support the scaling of Audrey AI’s technology and the expansion of its engineering and audit-focused teams as it grows its presence across Ireland, the UK, and other international markets.

    Audrey AI is targeting the global financial audit sector, valued at over $100 billion, where many workflows remain heavily manual. Its agentic AI platform is designed to automate key audit functions such as evidence collection and testing. Early pilot programmes with Top 10 and Top 20 audit firms have reportedly reduced time spent on data gathering, validation, and detailed testing by more than 85%, suggesting strong potential for the platform to become a critical tool for firms facing staffing constraints and margin pressures.

    For Mindflair, the investment aligns with its strategy of backing AI solutions that address complex challenges within regulated industries. The move highlights increasing investor focus on specialised AI applications capable of handling nuanced, domain-specific tasks that go beyond general-purpose systems, potentially improving both efficiency and audit quality across the accounting landscape.

    However, the company’s outlook remains tempered by limited visibility on revenue and weak cash-flow conversion, despite a notable rebound in reported profitability and a relatively low level of leverage. Market indicators point to a bearish technical setup, with the share price trading below key averages and a negative MACD reading. While valuation may appear low on a price-to-earnings basis, concerns around earnings quality reduce confidence in that metric.

    More about Mindflair plc

    Mindflair plc is an AIM-listed investment firm offering exposure to a portfolio of emerging technology businesses centred on artificial intelligence. Its investment approach focuses on high-growth areas such as the Internet of Things, cybersecurity, machine learning, immersive technologies, and big data, targeting companies with strong commercial traction and the potential to scale rapidly.

  • Narf Industries Grows Revenue and Secures $2.5m U.S. Deal Amid AI Platform Shift

    Narf Industries Grows Revenue and Secures $2.5m U.S. Deal Amid AI Platform Shift

    Narf Industries (LSE:NARF) reported unaudited revenue of around $4.2 million for the year ended 31 March 2026, rising from $3.0 million in the prior period. The increase was largely supported by its government-funded research and development work, alongside a contracted backlog of about $5.3 million scheduled for FY27. The company noted that expansion continues to be financed internally, supported by a CEO loan facility rather than external fundraising, while ongoing discussions with leading application security firms points to strengthening interest in its technology.

    On the strategic front, the company has rebranded its Ranger.ai platform as UPxi, repositioning it as a scalable Agentic AI solution designed to identify cybersecurity vulnerabilities early within open source software ecosystems. This transition has already delivered a low six-figure commercial agreement through a major systems integrator. Following the reporting period, Narf also secured a new U.S. government R&D contract valued at more than $2.5 million, enhancing revenue visibility and reinforcing its move toward a platform-based, partner-led business model rather than one-off project work.

    Despite these developments, the company’s outlook remains constrained by financial pressures, including widening losses, negative equity, and a return to cash outflows. From a market perspective, technical indicators suggest some stability, with the share price holding above key moving averages and maintaining steady momentum. However, valuation remains difficult to justify given the lack of profitability and absence of a dividend.

    More about Narf Industries plc

    Narf Industries plc is a U.S.-focused cybersecurity company specializing in advanced threat intelligence, government-backed R&D, and software security solutions tailored to national security and critical infrastructure sectors. Its core product, UPxi, is an Agentic AI platform aimed at detecting risks within open source software supply chains at an early stage, helping prevent vulnerabilities from propagating into downstream systems.

  • Union Jack Oil Flags Minor Timing Slip for Oklahoma Crossroads Well

    Union Jack Oil Flags Minor Timing Slip for Oklahoma Crossroads Well

    Union Jack Oil (LSE:UJO) has announced a slight postponement to the spud date for the Crossroads well in southern Oklahoma. The delay follows maintenance requirements identified by operator Reach Oil and Gas Company Inc., with drilling now expected to begin before the end of April 2026, suggesting only limited disruption to the overall schedule.

    Union Jack retains a 43% stake in the project and has already covered its share of drilling expenditures using available cash. This confirms the well is fully funded, and the revised timeline is not expected to place pressure on the company’s short-term finances or alter its broader plan to strengthen its onshore presence in the United States.

    From a financial perspective, the group continues to benefit from a debt-free balance sheet and consistent profitability since 2022. However, performance has been weighed down by a sharp decline in profitability during 2024, alongside uneven and negative free cash flow trends. Market indicators point to near-term momentum, though conditions appear overbought, and the longer-term trend remains less robust. Valuation metrics are also challenging to assess, given the absence of a meaningful P/E ratio and dividend yield.

    More about Union Jack Oil

    Union Jack Oil is an AIM-listed oil and gas company engaged in onshore production, development, exploration, and investment across the UK and the United States. Its strategy centers on conventional hydrocarbon projects, with stakes in a range of drilling and producing assets, aiming to build a portfolio of reliable, cash-generating operations within established energy regions.

  • Wall Street Poised for Cautious Open as Middle East Tensions Cloud Outlook: Dow Jones, S&P, Nasdaq, Futures

    Wall Street Poised for Cautious Open as Middle East Tensions Cloud Outlook: Dow Jones, S&P, Nasdaq, Futures

    U.S. equity futures were little changed early Wednesday, pointing to a muted start as markets pause following two sessions of strong gains.

    Investors appear hesitant to extend the rally, which recently pushed both the Nasdaq and the S&P 500 to their highest closing levels in more than two months.

    Lingering uncertainty around the Middle East conflict is also keeping some traders on the sidelines, with attention focused on the possibility of another round of U.S.-Iran negotiations.

    Speaking to Fox Business, President Donald Trump said the conflict is “very close to over” and reiterated that Iran wants to strike a deal “very badly.”

    He also suggested that the “stock market is going to boom” once tensions between the U.S., Israel and Iran are resolved.

    Despite the recent rally, AJ Bell investment director Russ Mould warned that “there remains considerable uncertainty over a successful outcome from peace negotiations.”

    Stocks rallied sharply on Tuesday, building on Monday’s gains, with major indices closing firmly higher and technology stocks leading the advance.

    By the end of the session, the main benchmarks were at or near their highs. The Nasdaq rose 455.35 points, or 2%, to 23,639.08, the S&P 500 added 81.14 points, or 1.2%, to 6,967.38, and the Dow Jones Industrial Average gained 317.74 points, or 0.7%, to 48,535.99.

    The sustained advance lifted both the Nasdaq and the S&P 500 to their strongest closing levels in over two months, while the Dow reached a one-month high.

    Market sentiment has been supported in part by optimism around a potential second phase of U.S.-Iran talks aimed at resolving the conflict.

    Earlier in the week, President Donald Trump said the U.S. had been approached by Iran regarding renewed discussions, adding, “They’d like to make a deal very badly.”

    In a subsequent interview with the New York Post, he said a follow-up round of talks “could be happening over next two days.”

    Expectations of diplomatic progress have weighed on oil prices, with U.S. crude futures falling 7%.

    “Previously, the narrative was straightforward: the longer the war dragged on, the worse the outlook for growth, inflation and risk assets,” said Daniela Hathorn, Senior Market Analyst at Capital.com. “Now, the dynamic appears to have flipped.”

    “With a ceasefire framework still loosely in place and the US attempting to control the Strait, the absence of escalation, rather than the presence of conflict, is being treated as a positive signal,” she added. “In other words, each day without a major disruption to Gulf energy infrastructure is being read as incremental progress toward stabilization.”

    Further supporting sentiment, data from the Labor Department showed U.S. producer prices rose less than expected in March.

    The producer price index for final demand increased 0.5% in March, matching a downwardly revised figure for February.

    Economists had forecast a 1.2% increase, compared with an initially reported 0.7% gain in the prior month.

    On an annual basis, producer prices rose 4.0% in March, up from 3.4% in February, but below expectations of 4.6%.

    Airline stocks led gains across sectors, with the NYSE Arca Airline Index jumping 5.1%.

    Brokerage stocks also advanced, as reflected by a 2.4% rise in the NYSE Arca Broker/Dealer Index.

    Biotech, retail and semiconductor stocks posted notable gains, while energy shares declined sharply alongside falling oil prices.

  • European Stocks Trade Mixed as Earnings Diverge and Iran-U.S. Talks Loom: DAX, CAC, FTSE100

    European Stocks Trade Mixed as Earnings Diverge and Iran-U.S. Talks Loom: DAX, CAC, FTSE100

    European equities showed little clear direction on Wednesday, as investors assessed a mixed batch of corporate earnings while also preparing for a potential new round of face-to-face negotiations between the United States and Iran, which could begin as early as this weekend.

    Reports suggest Washington has outlined two fresh conditions ahead of any renewed dialogue. According to Israel Hayom, the U.S. is seeking a full and unrestricted reopening of the Strait of Hormuz and continues to emphasize a reciprocal approach in negotiations.

    On the macroeconomic front, updated data from France’s statistics agency INSEE showed that harmonized consumer price inflation for March came in slightly higher than initially estimated.

    EU-harmonized inflation reached 2.0% for the month, above the preliminary reading of 1.9% and up from 1.1% in February.

    Domestic consumer price inflation in France was confirmed at 1.7%, rising from 0.9% the previous month and marking the fastest pace of increase since August 2024.

    Meanwhile, Eurostat reported that industrial production across the eurozone rose 0.4% in February compared with January.

    In equity markets, France’s CAC 40 was down 0.6%, while the UK’s FTSE 100 hovered around flat levels and Germany’s DAX edged up 0.1%.

    Hermes International (EU:RMS) dropped 10% after reporting slower first-quarter sales growth.

    Stellantis (BIT:STLAM) climbed 3.4% after announcing a 12% increase in global vehicle shipments for the first quarter.

    ASML (EU:ASML) gained 1.7% after lifting its 2026 sales outlook, supported by first-quarter results that exceeded expectations.

    Aegon (EU:AGN) declined nearly 2% following an agreement to sell its UK operations to Standard Life in a deal valued at £2 billion.

    Rank Group (LSE:RNK) surged 11% in London after raising its full-year underlying operating profit guidance, supported by a 5% year-on-year increase in fiscal third-quarter net gaming revenue.

    Antofagasta (LSE:ANTO) rose 3.2%. Despite reporting a decline in first-quarter copper output, the company said it expects production to increase progressively over the rest of the year.